English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA decision model found that the relative clinical benefit of left atrial appendage occlusion (LAAO) and oral anticoagulants (OAC) in patients with atrial fibrillation depends on the patients’ baseline risks for stroke and bleeding. LAAOs were found to be the preferred strategy in those with the highest bleeding risk. This benefit became less certain with increasing risk for ischemic stroke and decreasing bleeding risk. The findings are published in Annals of Internal Medicine.
Tag: atrial fibrillation (AF)
Atrial fibrillation after non-cardiac surgery is common and not benign
A cohort study of persons with incident atrial fibrillation (AF) has found that AF after noncardiac surgery is common and comprises 13 percent of all new AF diagnoses. Postoperative AF is also associated with similar risk for stroke or transient ischemic attack (TIA) and death as AF unrelated to surgery. The findings are published in Annals of Internal Medicine.
Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement
Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial
The Valley Hospital is First Center in the World to Utilize WATCHMAN™ TruPlan™ CT Imaging Software
The Valley Hospital in Ridgewood, NJ, has become the first center in the world to utilize leading-edge imaging software designed to enhance the safety and efficacy of a Watchman implant procedure.
Study Shows Ablation Procedure More Effective Than Medications for Initial Treatment of Atrial Fibrillation
Cleveland: Cleveland Clinic researchers have found that cryoballoon ablation as the initial treatment for atrial fibrillation is more effective than current standard-of-care management using medications. The study was published today in the New England Journal of Medicine.
Trial Finds High Doses of a Prescription Fish Oil Do Not Reduce Major Cardiac Events in High-Risk Patients
Cleveland: Findings from a new Cleveland Clinic study do not support the use of a high dose omega-3 fatty acid formulation to reduce major adverse cardiovascular events in patients with high cardiovascular risk.
Findings from the STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) In Patients With High Vascular Risk And Atherogenic Dyslipidemia were reported today during a Late Breaking Science session at the American Heart Association’s virtual Scientific Sessions 2020. The findings were also simultaneously published online in the Journal of the American Medical Association.
Mount Sinai Cardiologists First on East Coast to Offer New Stroke Prevention Therapy for Heart Patients
New generation implant has improved safety and performance features for those with atrial fibrillation